Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - BICC1 |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - BICC1 | intrahepatic cholangiocarcinoma | predicted - sensitive | FGFR2 Inhibitor | Derazantinib | Case Reports/Case Series | Actionable | In a Phase Ib/II trial, treatment with Derazantinib (ARQ 087) in four patients with intrahepatic cholangiocarcinoma harboring FGFR2-BICC1 resulted in one partial response, stable disease in two, and progressive disease in one (PMID: 30420614; NCT01752920). | 30420614 |
FGFR2 - BICC1 | cholangiocarcinoma | predicted - sensitive | Sorafenib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with cholangiocarcinoma harboring FGFR2-BICC1 achieved a partial response with a reduction in tumor size after one month of Nexavar (sorafenib) treatment (PMID: 31807010). | 31807010 | |
FGFR2 - BICC1 | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) inhibited Fgfr phosphorylation and downstream signaling, resulted in growth inhibition of transformed cells expressing FGFR2-BICC1 in culture (PMID: 28416604). | 28416604 |
FGFR2 - BICC1 | intrahepatic cholangiocarcinoma | predicted - sensitive | FGFR Inhibitor (Pan) | Futibatinib | Case Reports/Case Series | Actionable | In a Phase II trial (FOENIX-CCA2), Futibatinib (TAS-120) demonstrated manageable toxicity profile, resulted in an objective response rate (ORR) of 37.3% (25/67), a median duration of response of 8.3 months, and a disease control rate of 82% in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions (82%) or other rearrangements (18%), ORR was 33.3% (5/15) in patients harboring FGFR2-BICC1 fusion (Annals of Oncology (2020) 31 (suppl_4): S261-S262; NCT02052778). | detail... |
FGFR2 - BICC1 | intrahepatic cholangiocarcinoma | predicted - sensitive | FGFR Inhibitor (Pan) | Futibatinib | Case Reports/Case Series | Actionable | In a Phase I trial (FOENIX-101), Futibatinib (TAS-120) treatment resulted in a partial response in two patients with intrahepatic cholangiocarcinoma harboring FGFR2-BICC1 fusion (PMID: 32622884; NCT02052778). | 32622884 |
FGFR2 - BICC1 | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical | Actionable | In a preclinical study, treatment with Infigratinib (BGJ398) prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810). | 24122810 |
FGFR2 - BICC1 | Advanced Solid Tumor | sensitive | PD173074 | Preclinical | Actionable | In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810). | 24122810 | |
FGFR2 - BICC1 | cholangiocarcinoma | sensitive | FGFR2 Inhibitor | Pemigatinib | Phase II | Actionable | In a Phase II (FIGHT-202) trial, Pemazyre (pemigatinib) treatment resulted in an objective response rate (ORR) of 35.5% (38/107, 3 complete response, 35 partial response) in patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements, 29% (31/107) of the patients harbored FGFR2-BICC1 and achieved an ORR (32.3%, 10/31) and a median progression-free survival (6.80 vs 6.93 months) comparable to the entire group (PMID: 32203698; NCT02924376). | 32203698 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|